Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease
暂无分享,去创建一个
[1] A. Leite-Moreira,et al. Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes , 2015, Cardiovascular Diabetology.
[2] Amanda N Haile,et al. Supplemental Figure 1 , 2014 .
[3] Alan D. Lopez,et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2014, The Lancet.
[4] V. Fuster. Global burden of cardiovascular disease: time to implement feasible strategies and to monitor results. , 2014, Journal of the American College of Cardiology.
[5] J. Tijssen,et al. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. , 2014, JAMA.
[6] D. J. Veldhuisen,et al. Chronic Metformin Treatment is Associated with Reduced Myocardial Infarct Size in Diabetic Patients with ST-segment Elevation Myocardial Infarction , 2014, Cardiovascular Drugs and Therapy.
[7] A. Leite-Moreira,et al. METformin in DIastolic Dysfunction of MEtabolic Syndrome (MET-DIME) Trial: Rationale and Study Design , 2014, Cardiovascular Drugs and Therapy.
[8] G. Rena,et al. Molecular mechanism of action of metformin: old or new insights? , 2013, Diabetologia.
[9] H. Kwon,et al. Adipokines Mediate Inflammation and Insulin Resistance , 2013, Front. Endocrinol..
[10] Z. Fortes,et al. Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats. , 2013, International journal of cardiology.
[11] R. Arena,et al. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. , 2013, JACC. Heart failure.
[12] A. Luchner,et al. Antidiabetic treatment restores adiponectin serum levels and APPL1 expression, but does not improve adiponectin-induced vasodilation and endothelial dysfunction in Zucker diabetic fatty rats , 2013, Cardiovascular Diabetology.
[13] G. Rongen,et al. Metformin Therapy in Diabetes: The Role of Cardioprotection , 2013, Current Atherosclerosis Reports.
[14] C. Lang,et al. Insulin sensitization therapy and the heart: focus on metformin and thiazolidinediones. , 2012, Heart failure clinics.
[15] M. Pletcher,et al. Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial , 2012, Journal of hypertension.
[16] K. Nair,et al. Effect of insulin sensitizer therapy on atherothrombotic and inflammatory profiles associated with insulin resistance. , 2012, Mayo Clinic proceedings.
[17] K. Eckardt,et al. Inflammation and metabolic dysfunction: links to cardiovascular diseases. , 2012, American journal of physiology. Heart and circulatory physiology.
[18] T. Marwick,et al. Integrated backscatter as a fibrosis marker in the metabolic syndrome: association with biochemical evidence of fibrosis and left ventricular dysfunction. , 2012, European heart journal cardiovascular Imaging.
[19] D. Hardie,et al. AMPK: a nutrient and energy sensor that maintains energy homeostasis , 2012, Nature Reviews Molecular Cell Biology.
[20] P. Netti,et al. Metformin Prevents the Development of Chronic Heart Failure in the SHHF Rat Model , 2012, Diabetes.
[21] S. Grundy. Pre-diabetes, metabolic syndrome, and cardiovascular risk. , 2012, Journal of the American College of Cardiology.
[22] J. G. Reyes-García,et al. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial , 2012, Journal of pediatric endocrinology & metabolism : JPEM.
[23] B. Stratmann,et al. Heart in Diabetes: Not Only a Macrovascular Disease , 2011, Diabetes Care.
[24] Shunichi Homma,et al. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. , 2011, Journal of the American College of Cardiology.
[25] C. Buechler,et al. Globular and full-length adiponectin induce NO-dependent vasodilation in resistance arteries of Zucker lean but not Zucker diabetic fatty rats. , 2011, American journal of hypertension.
[26] Fengjuan Yao,et al. Metformin attenuates ventricular hypertrophy by activating the AMP‐activated protein kinase–endothelial nitric oxide synthase pathway in rats , 2011, Clinical and experimental pharmacology & physiology.
[27] A. Beck‐Sickinger,et al. Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors , 2010, Biological chemistry.
[28] Yi Zhu,et al. Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. , 2010, Cardiovascular research.
[29] C. Jellis,et al. Assessment of nonischemic myocardial fibrosis. , 2010, Journal of the American College of Cardiology.
[30] B. Viollet,et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. , 2010, The Journal of clinical investigation.
[31] S. Hawley,et al. Use of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK Activation , 2010, Cell metabolism.
[32] M. Ludgate,et al. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. , 2009, The Journal of clinical endocrinology and metabolism.
[33] M. Takeuchi,et al. Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration. , 2009, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[34] M. Mocanu,et al. Metformin Prevents Myocardial Reperfusion Injury by Activating the Adenosine Receptor , 2009, Journal of cardiovascular pharmacology.
[35] S. Jha,et al. Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart Failure , 2009, Circulation research.
[36] R. Sacco,et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. , 2008, The American journal of cardiology.
[37] G. Bhamra,et al. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening , 2008, Basic Research in Cardiology.
[38] R. Freeman,et al. Leptin: Linking obesity, the metabolic syndrome, and cardiovascular disease , 2008, Current hypertension reports.
[39] S. Jha,et al. Acute Metformin Therapy Confers Cardioprotection Against Myocardial Infarction Via AMPK-eNOS–Mediated Signaling , 2008, Diabetes.
[40] E. Salpeter,et al. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. , 2008, The American journal of medicine.
[41] Benjamin D. Levine,et al. Cardiac Steatosis in Diabetes Mellitus: A 1H-Magnetic Resonance Spectroscopy Study , 2007, Circulation.
[42] E. Abel,et al. Diabetic cardiomyopathy revisited. , 2007, Circulation.
[43] C. Rihal,et al. Association of obesity with left ventricular remodeling and diastolic dysfunction in patients without coronary artery disease. , 2006, The American journal of cardiology.
[44] Feng Liu,et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function , 2006, Nature Cell Biology.
[45] B. Viollet,et al. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. , 2006, Diabetes.
[46] David V. Power,et al. Standards of Medical Care in Diabetes: Response to position statement of the American Diabetes Association , 2006 .
[47] Fernando Costa,et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.
[48] A. Legrand,et al. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. , 2005, Metabolism: clinical and experimental.
[49] P. Scherer,et al. Adiponectin – journey from an adipocyte secretory protein to biomarker of the metabolic syndrome , 2005, Journal of internal medicine.
[50] D. Yellon,et al. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. , 2003, Journal of molecular and cellular cardiology.
[51] D. Yellon,et al. Myocardial Protection by Insulin at Reperfusion Requires Early Administration and Is Mediated via Akt and p70s6 Kinase Cell-Survival Signaling , 2001, Circulation research.
[52] F. Maklady,et al. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. , 2001, The American journal of cardiology.
[53] M. Owen,et al. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.
[54] D. Latchman,et al. Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. , 2000, Journal of molecular and cellular cardiology.
[55] K. Ohmori,et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. , 2000, Circulation.
[56] T Nakamura,et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. , 1999, Biochemical and biophysical research communications.
[57] R. Holman,et al. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.
[58] R. V. Sharma,et al. Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. , 1996, American journal of hypertension.
[59] B. Spiegelman,et al. AdipoQ Is a Novel Adipose-specific Gene Dysregulated in Obesity (*) , 1996, The Journal of Biological Chemistry.
[60] J. Yudkin,et al. Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groups , 1993, Diabetes Care.
[61] K. Landin-Wilhelmsen. Metformin and blood pressure , 1992, Journal of clinical pharmacy and therapeutics.
[62] H. Gin,et al. Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics. , 1989, Diabetes research and clinical practice.
[63] F. Ross,et al. Use of Cells Expressing gamma Subunit Variants to Identify Diverse Mechanisms of AMPK Activation , 2010 .
[64] H. Minuk,et al. Metabolic syndrome. , 2005, Journal of insurance medicine.
[65] R. Krauss,et al. Diagnosis and management of the metabolic syndrome , 2005 .
[66] F. Gao,et al. Ischemia-Reperfusion : The Roles of PI 3-Kinase , Akt , and Endothelial Nitric Oxide Nitric Oxide Mediates the Antiapoptotic Effect of Insulin in Myocardial , 2002 .